46 results on '"Calcified coronary lesions"'
Search Results
2. Novel insights on dual antiplatelet therapy duration following stenting for angiography-detected moderate-to-severe calcified coronary lesions.
- Author
-
Lin Z, Yuan S, He J, Song Y, Zhang W, and Dou K
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Coronary Angiography, Aspirin therapeutic use, Aspirin administration & dosage, Hemorrhage chemically induced, Prospective Studies, Treatment Outcome, Registries, Vascular Calcification diagnostic imaging, Purinergic P2Y Receptor Antagonists therapeutic use, Purinergic P2Y Receptor Antagonists administration & dosage, Purinergic P2Y Receptor Antagonists adverse effects, Time Factors, Platelet Aggregation Inhibitors therapeutic use, Platelet Aggregation Inhibitors administration & dosage, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Coronary Artery Disease drug therapy, Percutaneous Coronary Intervention adverse effects, Dual Anti-Platelet Therapy methods, Drug-Eluting Stents
- Abstract
Dual antiplatelet therapy (DAPT), comprising both aspirin and the P2Y
12 receptor inhibitor, is crucial in managing patients with coronary artery disease following percutaneous coronary intervention (PCI). The optimal duration for DAPT in patients with angiography-detected moderate-to-severe calcified coronary (MSCC) lesions who underwent PCI with drug-eluting stents (DES) implantation remains uncertain. We recruited patients with angiography-detected MSCC lesions who received DES implantation from the prospective Fuwai Percutaneous Coronary Intervention Registry. Patients were classified into two groups according to the duration of DAPT: those with a DAPT duration of one year or less, and those with a DAPT duration of more than one year. The primary endpoint was the major adverse cardiovascular and cerebrovascular event, which was defined as composed of all-cause death, nonfatal myocardial infarction, or nonfatal stroke. The key-safety endpoint was bleeding type 2, 3, or 5 according to the Bleeding Academic Research Consortium criteria. There were 1730 patients included in the study, and 470 (27.17 %) continued DAPT for more than one year after undergoing MSCC-PCI with DES implantation. The median follow-up time was 2.5 years. DAPT>1-year versus ≤1-year DAPT was significantly associated with a reduced risk of the primary outcome (1.59 % versus 3.19 %; adjusted hazard ratio=0.44; 95 % CI: 0.22-0.88). Similar trends were observed for all-cause death (0.16 % versus 1.91 %; P<0.001) and cardiovascular death (0.08 % versus 1.06 %; P=0.001). There was no significant difference in the key-safety endpoint between 2 regimens (1.75 % versus 0.85 %; adjusted hazard ratio=1.95; 95 % CI: 0.65-5.84). In conclusion, long-term DAPT after DES implantation in patients with MSCC lesions resulted in improved clinical outcomes at 2.5 years. This was achieved by reducing the risk of ischemia without increasing clinically significant bleeding., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
3. Intravascular lithotripsy compared with rotational atherectomy for calcified coronary lesions: A meta-analysis of outcomes.
- Author
-
Gupta R, Hosseinpour A, Patel C, Malik AH, Goel A, Bandyopadhyay D, Basir MB, Lavie CJ, Patel NC, and Bhatt DL
- Subjects
- Humans, Treatment Outcome, Risk Factors, Male, Aged, Female, Atherectomy, Coronary adverse effects, Lithotripsy, Vascular Calcification diagnostic imaging, Vascular Calcification therapy, Coronary Artery Disease therapy, Coronary Artery Disease diagnostic imaging
- Abstract
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Bhatt discloses the following relationships - Advisory Board: Angiowave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys; Board of Directors: Angiowave (stock options), Boston VA Research Institute, Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock), Society of Cardiovascular Patient Care, TobeSoft; Chair: Inaugural Chair, American Heart Association Quality Oversight Committee; Consultant: Broadview Ventures, Hims; Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial); Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), CSL Behring (AHA lecture), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co‑leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees), Wiley (steering committee); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent); Research Funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Otsuka, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio; Royalties: Elsevier (Editor, Braunwald's Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Takeda.
- Published
- 2024
- Full Text
- View/download PDF
4. Between a Rock and a Hard Place: Technological Progress in Treating Calcified Coronary Lesions.
- Author
-
Savage MP, Fischman DL, and Mamas MA
- Subjects
- Humans, Treatment Outcome, Heart, Coronary Angiography, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Atherectomy, Coronary adverse effects, Vascular Calcification diagnostic imaging, Vascular Calcification therapy, Percutaneous Coronary Intervention adverse effects
- Abstract
Competing Interests: Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Published
- 2024
- Full Text
- View/download PDF
5. Orbital atherectomy safety and efficacy: A comparative analysis of ostial versus non-ostial calcified coronary lesions.
- Author
-
Ghazzal A, Martinsen BJ, Sendil S, Torres CA, Croix GS, Sethi P, Cipriano R, Kirtane AJ, Leon MB, and Beohar N
- Subjects
- Humans, Male, Middle Aged, Aged, Aged, 80 and over, Female, Retrospective Studies, Treatment Outcome, Coronary Angiography, Atherectomy, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Coronary Artery Disease etiology, Percutaneous Coronary Intervention adverse effects, Drug-Eluting Stents, Vascular Calcification diagnostic imaging, Vascular Calcification therapy, Vascular Calcification etiology, Atherectomy, Coronary adverse effects
- Abstract
Background: The safety and efficacy of coronary orbital atherectomy (OA) for treatment of ostial lesions are not yet fully established. We sought to evaluate (OA) treatment of severely calcified ostial and non-ostial lesions., Methods: A retrospective analysis of subjects treated with OA for severely calcified ostial and non-ostial lesions, at the Mount Sinai Medical Center, Miami Beach, Florida (MSMCMB) from January 2014 to September 2020, was completed. Study baseline characteristics, lesion and vessel characteristics, procedural outcomes, and in-hospital major adverse cardiovascular events (MACE) were analyzed and compared., Results: A total of 609 patients that underwent PCI with OA were identified. The majority of patients (81.9 %) had non-ostial lesions, while 16.6 % had ostial lesions (of which 2.8 % classified as aorto-ostial) and 1.5 % had unknown lesion anatomy. The mean age of the overall cohort was 74.0 ± 9.3 years, and 63.5 % were male. All patients received drug-eluting stent (DES) placement, and the overall freedom from MACE was 98.5 %, with no significant difference observed between the ostial and non-ostial groups. The freedom from cardiac death and MI was also similar between the two groups. There were low rates of bleeding complications and severe angiographic complications, and no persistent slow flow/no reflow was reported., Conclusions: This study demonstrated no significant differences in in-hospital MACE outcomes between patients with ostial versus non-ostial lesions, indicating that OA is a safe and effective treatment option for both lesion types, including those classified as aorto-ostial., Competing Interests: Declaration of competing interest NB, MBL, and AJK report receiving consulting fees from Cardiovascular Systems, Inc. (CSI). BJM is employed by and owns stock in CSI. No other potential conflict of interest relevant to this article was reported., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. The Supportive Guidewire Paradox: How Extra Support Guidewires May Hinder Equipment Delivery Through Tortuous and Calcified Coronary Lesions.
- Author
-
Mahowald MK, Chami T, and Brilakis ES
- Subjects
- Humans, Coronary Angiography, Equipment Design, Heart, Stents, Treatment Outcome, Angioplasty, Balloon, Coronary, Percutaneous Coronary Intervention, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy
- Abstract
Percutaneous coronary intervention of heavily calcified coronary vessels can be challenging due to difficult equipment delivery and suboptimal stent expansion, leading to worse clinical outcomes. Supportive guidewires are designed to facilitate equipment delivery. We present two cases of heavily calcified and tortuous coronary lesions in which use of support guidewires hindered balloon and stent delivery, possibly by increasing friction between equipment and the wall of the coronary vessel. Equipment delivery was achieved using less supportive workhorse guidewires., Competing Interests: Declaration of competing interest, (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
7. Randomized ComparIson of Strategies to PrepAre SeveRely CALCified Coronary Lesions 2: Design and Rationale of the ISAR-CALC 2 Trial.
- Author
-
Scalamogna M, Abdel-Wahab M, Mashayekhi K, Fusaro M, Leistner DM, Ayoub M, Xhepa E, Joner M, Kastrati A, Cassese S, and Rheude T
- Subjects
- Humans, Coronary Angiography, Prospective Studies, Treatment Outcome, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Coronary Artery Disease etiology, Angioplasty, Balloon, Coronary adverse effects, Angioplasty, Balloon, Coronary methods, Drug-Eluting Stents, Vascular Calcification diagnostic imaging, Vascular Calcification therapy, Vascular Calcification etiology, Atherectomy, Coronary adverse effects
- Abstract
Background: The percutaneous treatment of severely calcified coronary lesions has been associated with lower performance of coronary stents and poor clinical long-term outcomes. Adequate lesion preparation before stent implantation is of paramount importance to minimize the risk of stent failure. Balloon-based techniques for lesion preparation have been the subject of numerous investigations, albeit comparative data from randomized trials are scarce., Study Design and Objectives: The ISAR-CALC 2 (ClinicalTrials.gov: NCT05072730) is an investigator-initiated, prospective, randomized, multicentre, assessors-blind, open-label trial designed to compare a lesion preparation strategy with either super high-pressure balloon or intravascular lithotripsy (IVL) before drug-eluting stent (DES) implantation in patients with severely calcified, undilatable coronary lesions. In total, 80 patients are required for trial completion. The primary endpoint will be final angiographic minimal lumen diameter (MLD) after stent implantation. Key secondary endpoints include stent expansion assessed by optical coherence tomography (OCT), procedural and strategy success, need for complementary lesion preparation with rotational atherectomy, acute lumen gain, and major adverse cardiac events up to 30-day follow-up., Conclusions: The ISAR-CALC 2 trial aims to demonstrate the superiority of a lesion preparation strategy with a super high-pressure balloon as compared with intravascular lithotripsy prior to DES implantation in patients with severely calcified undilatable coronary lesions., Competing Interests: Declaration of competing interest Dr. Rheude has received speaker fees from SIS Medical and AstraZeneca. Dr. Joner reports institutional grant support from Boston Scientific, Cardiac Dimensions, Edwards Lifesciences, and Infraredx; consulting fees from Biotronik, TriCares, Veryan, and Shockwave; speaker fees from Abbott, AstraZeneca, Biotronik, Boston Scientific, Cardiac Dimensions, Edwards Lifesciences, Recor Medical and Shockwave; participation on a Steering Committee of Biotronik and Edwards Lifesciences; travel support from Boston Scientific, Cardiac Dimensions, Edwards Lifesciences and SIS Medical. Dr. Abdel-Wahab reports that his hospital received speaker honoraria and/or consulting fees on his behalf from Medtronic and Boston Scientific. Dr. Cassese reports lecture/proctoring honoraria from SIS Medical, AstraZeneca, Boston Scientific, and Teleflex; and grants to the institution from SIS Medical, Boston Scientific, Abiomed, and Abbott Vascular. All other authors have no relevant conflicts of interest to declare., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
8. Efficacy and Safety of Intravascular Lithotripsy Versus Rotational Atherectomy in Balloon-Crossable Heavily Calcified Coronary Lesions.
- Author
-
Mousa MAA, Bingen BO, Al Amri I, Mertens BJA, Taha S, Tohamy A, Youssef A, Jukema JW, and Montero-Cabezas JM
- Subjects
- Humans, Heart, Treatment Outcome, Coronary Angiography, Atherectomy, Coronary adverse effects, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Angioplasty, Balloon, Coronary adverse effects, Lithotripsy, Vascular Calcification diagnostic imaging, Vascular Calcification therapy
- Abstract
Competing Interests: Declaration of competing interest The Department of Cardiology of the Leiden University Medical Center received unrestricted research grants from Abbott Vascular, Bayer, Bioventrix, Biotronik, Boston Scientific, Edwards Lifesciences, GE Healthcare and Medtronic. JM Montero-Cabezas received speaker fees from Boston Scientific and Abiomed, consulting fees from Penumbra Inc. and research grants from Shockwave Medical. The rest of the authors have no further conflicts of interest to declare.
- Published
- 2023
- Full Text
- View/download PDF
9. Assessment of Post-Dilatation Strategies for Optimal Stent Expansion in Calcified Coronary Lesions: Ex Vivo Analysis With Optical Coherence Tomography.
- Author
-
Dallan LAP, Zimin VN, Lee J, Gharaibeh Y, Kim JN, Pereira GTR, Vergara-Martel A, Dong P, Gu L, Wilson DL, and Bezerra HG
- Subjects
- Calcium, Coronary Angiography methods, Coronary Vessels diagnostic imaging, Dilatation, Humans, Stents, Tomography, Optical Coherence, Treatment Outcome, Angioplasty, Balloon, Coronary adverse effects, Angioplasty, Balloon, Coronary methods, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy
- Abstract
Introduction: Interventional cardiologists make adjustments in the presence of coronary calcifications known to limit stent expansion, but proper balloon sizing, plaque-modification approaches, and high-pressure regimens are not well established. Intravascular optical coherence tomography (IVOCT) provides high-resolution images of coronary tissues, including detailed imaging of calcifications, and accurate measurements of stent deployment, providing a means for detailed study of stent deployment., Objective: Evaluate stent expansion in an ex vivo model of calcified coronary arteries as a function of balloon size and high-pressure, post-dilatation strategies., Methods: We conducted experiments on cadaver hearts with calcified coronary lesions. We assessed stent expansion as a function of size and pressure of non-compliant (NC) balloons (i.e., nominal, 0.5, 1.0, and 1.5 mm balloons at 10, 20 and 30 atm). IVOCT images were acquired pre-stent, post-stent, and at all post-dilatations. Stent expansion was calculated using minimum expansion index (MEI)., Results: We analyzed 134 IVOCT pullbacks from ten ex-vivo experiments. The mean distal and proximal reference lumen diameters were 2.2 ± 0.5 mm and 2.5 ± 0.7 mm, respectively, 80% of times using a 3.0 mm diameter stent. Overall, based on stent sizing, a good expansion (MEI ≥ 80%) was reached using the 1:1 NC balloon at 20 atm, and expansion > 100% was reached using the 1:1 NC balloon at 30 atm. In the subgroup analysis, comparing low-calcified and high-calcified lesions, good expansion (MEI ≥ 80%) was reached using the 1:1 NC balloon at nominal pressure (10 atm) versus using 1:1 NC balloon at 30 atm, respectively. Significant vessel rupture was identified in all the vessels mainly upon post-dilatation with larger balloons, and 60% of the experiments (6 vessels, 3 in each calcium subgroup) presented rupture with the +1.0 mm NC balloon at 20 atm., Conclusion: When treating calcified lesions, good stent expansion was reached using smaller balloons at higher pressures without coronary injuries, whereas bigger balloons yielded unpredictable expansion even at lower pressures and demonstrated potential harmful damages to the vessels. As these findings could help physicians with appropriate planning of stent post-dilatation for calcified lesions, it will be important to clinically evaluate the recommended protocol., Competing Interests: Declaration of competing interest None of the authors have conflicts of interest regarding this paper., (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
10. Rotational Atherectomy or Balloon-Based Techniques to Prepare Severely Calcified Coronary Lesions.
- Author
-
Rheude T, Fitzgerald S, Allali A, Mashayekhi K, Gori T, Cuculi F, Kufner S, Hemetsberger R, Sulimov DS, Rai H, Ayoub M, Bossard M, Xhepa E, Fusaro M, Toelg R, Joner M, Byrne RA, Richardt G, Kastrati A, Cassese S, and Abdel-Wahab M
- Subjects
- Coronary Angiography, Humans, Treatment Outcome, Angioplasty, Balloon, Coronary adverse effects, Angioplasty, Balloon, Coronary methods, Atherectomy, Coronary adverse effects, Atherectomy, Coronary methods, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Drug-Eluting Stents, Vascular Calcification diagnostic imaging, Vascular Calcification therapy
- Abstract
Background: The comparative efficacy of percutaneous techniques for the preparation of calcified lesions before stenting remains poorly studied., Objectives: This study sought to compare the performance of up-front rotational atherectomy (RA) or balloon-based techniques before drug-eluting stent implantation in severely calcified coronary lesions as assessed by angiography and optical coherence tomography (OCT)., Methods: Patient-level data from the PREPARE-CALC (Comparison of Strategies to Prepare Severely Calcified Coronary Lesions) and ISAR-CALC (Comparison of Strategies to Prepare Severely Calcified Coronary Lesions) randomized trials were pooled. The primary endpoint was stent expansion as assessed by OCT imaging. The secondary endpoints included stent eccentricity, stent asymmetry, angiographic acute lumen gain, strategy success and in-hospital occurrence of cardiac death, target vessel myocardial infarction, and repeat revascularization., Results: Among 274 patients originally randomized, 200 participants with available OCT data after lesion preparation with RA (n = 63), a modified balloon (MB, n = 103), or a super high-pressure balloon (n = 34) before stenting were analyzed. The use of RA versus MB or a super high-pressure balloon led to comparable stent expansion (73.2% ± 11.6% vs 70.8% ± 13.6% vs 71.8% ± 12.2%, P = 0.49) and stent asymmetry (P = 0.83). Compared with RA or MB, a super high-pressure balloon was associated with less stent eccentricity (P = 0.03) with a numerically higher acute lumen gain, albeit not significantly different (P = 0.08). Strategy success was more frequent with RA versus MB (P = 0.002) and numerically more frequent with RA versus a super high-pressure balloon (P = 0.06). Clinical outcomes did not differ between groups., Conclusions: In patients with severely calcified lesions undergoing drug-eluting stent implantation, lesion preparation with RA, MB, or a super high-pressure balloon was associated with comparable stent expansion. A super high-pressure balloon is associated with less stent eccentricity, whereas strategy success is more frequent with RA., Competing Interests: Funding Support and Author Disclosures The PREPARE-CALC trial was an investigator-initiated trial, which was financed by the Heart Center, Segeberger Kliniken GmbH, Bad Segeberg, Germany. The ISAR-CALC trial was an investigator-initiated trial, which was supported by a research grant from SIS Medical AG and Boston Scientific. Dr Rheude has received speaker fees from SIS Medical AG. Dr Allali has received speaker/proctoring honoraria from Boston Scientific and Biotronik. Dr Cuculi has received speaker and consulting fees from Abbott Vascular and SIS Medical AG. Dr Kufner has received speaker and consulting fees from AstraZeneca, Bristol Myers Squibb, and Translumina not related to the current work. Dr Bossard has received speaker and consulting fees from Abbott Vascular and SIS Medical AG. Dr Joner has received lecture fees and research grants from Edwards Lifesciences and Boston Scientific; and is a consultant for Biotronik and Orbus Neich. Dr Byrne has received research funding to the institution from Abbott Vascular, Biosensors, and Boston Scientific. Dr Cassese has received lectures/proctoring honoraria from SIS Medical AG; and has received research funding to the institution from SIS Medical AG and Boston Scientific for the conduct of the ISAR-CALC trial. Dr Abdel-Wahab reports that his hospital received speaker honoraria and/or consulting fees on his behalf from Medtronic and Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
11. Vascular Response Following Drug-Eluting Stent Implantation in Calcified Coronary Lesions: 2 Major Clinical Questions Emerged.
- Author
-
Kitabata H
- Subjects
- Coronary Angiography, Humans, Treatment Outcome, Angioplasty, Balloon, Coronary, Atherectomy, Coronary, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Drug-Eluting Stents, Vascular Calcification diagnostic imaging, Vascular Calcification therapy
- Published
- 2022
- Full Text
- View/download PDF
12. Bailout Intravascular Lithotripsy for the Treatment of Acutely Underexpanded Stents in Heavily Calcified Coronary Lesions: A Case Series.
- Author
-
Mousa MAA, Bingen BO, Amri IA, Digiacomo S, Karalis I, Jukema JW, and Montero-Cabezas JM
- Subjects
- Coronary Angiography, Humans, Stents, Treatment Outcome, Atherectomy, Coronary adverse effects, Atherectomy, Coronary methods, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Lithotripsy, Vascular Calcification diagnostic imaging, Vascular Calcification therapy
- Abstract
Stent underexpansion is a common problem in heavily calcified coronary lesions treated with percutaneous coronary intervention, and has been associated with in-stent restenosis, stent thrombosis and, subsequently, poor clinical outcomes. Adequate preparation of heavily calcified coronary lesions (e.g. using non-compliant balloons, cutting/scoring balloons, rotational/orbital atherectomy or intravascular lithotripsy) prior to stent implantation is essential in preventing stent underexpansion. However, in certain cases the deployed stent may remain underexpanded despite extensive lesion preparation. To date, no consensus exists on how to treat stent underexpansion in this scenario. We present a cases series in which post-stenting intravascular lithotripsy was performed to treat acute stent underexpansion in heavily calcified lesions, describing the technical aspects, angiographic results as well as clinical outcomes at mid-term follow-up., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
13. Orbital Atherectomy for Calcified Coronary Lesions Using the Scoring Balloon-Navigated Wire Bias (SCONB) Technique.
- Author
-
Kawagoe Y, Yoneda S, Fujino M, Otsuka F, and Noguchi T
- Subjects
- Atherectomy methods, Coronary Angiography methods, Humans, Treatment Outcome, Atherectomy, Coronary adverse effects, Atherectomy, Coronary methods, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease surgery, Vascular Calcification diagnostic imaging, Vascular Calcification surgery
- Published
- 2022
- Full Text
- View/download PDF
14. "RotaTripsy": Combination of Rotational Atherectomy and Intravascular Lithotripsy in Heavily Calcified Coronary Lesions: A Case Series.
- Author
-
Gonzálvez-García A, Jiménez-Valero S, Galeote G, Moreno R, López de Sá E, and Jurado-Román A
- Subjects
- Coronary Angiography, Humans, Treatment Outcome, Atherectomy, Coronary, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Lithotripsy, Percutaneous Coronary Intervention adverse effects, Vascular Calcification diagnostic imaging, Vascular Calcification therapy
- Abstract
Heavily calcified coronary lesions increase the complexity of percutaneous coronary interventions (PCI) and represent a challenge for interventional cardiologists. They are an important cause of stent underexpansion and poor clinical outcome. Nowadays, there are different dedicated devices which enhance the chances of success. Rotational atherectomy is the first-line modality which permits to cross balloons or stents through severe calcified lesions. However, when circumferential deep calcium plaques exist may not be enough to achieve adequate expansion of these devices. In these cases, the complementary use of intracoronary lithotripsy ("RotaTripsy") can be an effective approach that further modifies the calcified plaque and enables optimal stent implantation. We present the first case series undergoing PCI using "RotaTripsy" technique., Competing Interests: Declaration of competing interest Nothing to declare., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
15. Intravascular Lithotripsy for Treatment of Calcified Coronary Lesions: Patient-Level Pooled Analysis of the Disrupt CAD Studies.
- Author
-
Kereiakes DJ, Di Mario C, Riley RF, Fajadet J, Shlofmitz RA, Saito S, Ali ZA, Klein AJ, Price MJ, Hill JM, and Stone GW
- Subjects
- Coronary Angiography, Humans, Prospective Studies, Treatment Outcome, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Lithotripsy, Percutaneous Coronary Intervention adverse effects, Vascular Calcification diagnostic imaging, Vascular Calcification therapy
- Abstract
Objectives: The aim of this pooled analysis was to assess the cumulative safety and effectiveness of coronary intravascular lithotripsy (IVL)., Background: The clinical outcomes of IVL to optimize target lesion preparation in severely calcified de novo coronary stenoses have been examined in 4 prospective studies (Disrupt CAD I [NCT02650128], Disrupt CAD II [NCT03328949], Disrupt CAD III [NCT03595176], and Disrupt CAD IV [NCT04151628])., Methods: Patient data were pooled from the Disrupt CAD studies, which shared uniform study criteria, endpoint definitions and adjudication, and procedural follow-up. The primary safety endpoint was freedom from major adverse cardiovascular events (composite of cardiac death, all myocardial infarction, or target vessel revascularization) at 30 days. The primary effectiveness endpoint was procedural success, defined as stent delivery with a residual stenosis ≤30% by quantitative coronary angiography without in-hospital major adverse cardiovascular events. Secondary outcomes included serious angiographic complications, target lesion failure, cardiac death, and stent thrombosis at 30 days., Results: Between December 2015 and April 2020, 628 patients were enrolled at 72 sites from 12 countries. Presence of severe calcification was confirmed in 97.0% of target lesions with an average calcified segment length of 41.5 ± 20.0 mm. The primary safety and effectiveness endpoints were achieved in 92.7% and 92.4% of patients, respectively. At 30 days, the rates of target lesion failure, cardiac death, and stent thrombosis were 7.2%, 0.5%, and 0.8%. Rates of post-IVL and final serious angiographic complications were 2.1% and 0.3%, with no IVL-associated perforations, abrupt closure, or episodes of no reflow., Conclusions: In the largest cohort of patients treated with coronary IVL assessed to date, coronary IVL safely facilitated successful stent implantation in severely calcified coronary lesions with a high rate of procedural success., Competing Interests: Funding Support and Author Disclosures Dr. Kereiakes is a consultant for SINO Medical Sciences Technologies, Boston Scientific, Elixir Medical, Svelte Medical Systems, Caliber Therapeutics/Orchestra BioMed, and Shockwave Medical; and is a stockholder in Ablative Solutions. Dr. Riley has received honoraria from Boston Scientific, Asahi Intecc, and Medtronic. Dr. Di Mario has received research grants from Amgen, Behring, Chiesi, Daiichi-Sanyo, Edwards Lifesciences, Medtronic, Shockwave, and Volcano Philips. Dr. Shlofmitz is a speaker for Shockwave Medical. Dr. Saito is a consultant for Terumo and Japan Lifeline. Dr. Ali has received grants from the National Heart, Lung, and Blood Institute, Abbott Vascular, and Cardiovascular Systems; has received personal fees from Amgen, AstraZeneca, and Boston Scientific; and holds equity in Shockwave Medical. Dr. Price has received consulting and speaker honoraria from Abbott Vascular, Boston Scientific, Biosense Webster, Medtronic, Shockwave Medical, and W.L. Gore. Dr. Hill has received fees and grant support from Abbott Vascular, Boston Scientific, Abiomed, and Shockwave Medical; and is a stockholder in Shockwave Medical. Dr. Stone has received speaker honoraria from Cook Medical and Terumo; is a consultant for Valfix Medical, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, and CardioMech; and has equity and options from Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, the BioStar family of funds, SpectraWave, Orchestra BioMed, Aria, Cardiac Success, and Valfix. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
16. Orbital Atherectomy for the Treatment of Long (≥25-40 mm) Severely Calcified Coronary Lesions: ORBIT II Sub-Analysis.
- Author
-
Kumar G, Shin EY, Sachdeva R, Shlofmitz E, Behrens AN, Martinsen BJ, and Chambers JW
- Subjects
- Aged, Aged, 80 and over, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease mortality, Female, Humans, Male, Middle Aged, Myocardial Infarction mortality, Prospective Studies, Risk Assessment, Risk Factors, Severity of Illness Index, Stents, Time Factors, Treatment Outcome, United States, Vascular Calcification diagnostic imaging, Vascular Calcification mortality, Atherectomy, Coronary adverse effects, Atherectomy, Coronary mortality, Coronary Artery Disease therapy, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention instrumentation, Percutaneous Coronary Intervention mortality, Vascular Calcification therapy
- Abstract
Background: Orbital atherectomy (OA) is an effective method of lesion preparation of severely calcified vessels prior to stent deployment. Long calcified lesions may lead to higher risk of post-procedural complications, yet the optimal treatment strategy has not been established. In this study we sought to determine the safety and efficacy of OA in patients with long (≥25-40 mm) calcified target lesions., Methods: ORBIT II was a single-arm trial that enrolled 443 patients at 49 U.S. sites. De novo, severely calcified coronary lesions were treated with OA prior to stenting. Patients treated with the OA device were stratified into two groups according to target lesion length as visually estimated by the investigator: those with short (<25 mm; N = 314) vs. long (≥25-40 mm; N = 118) lesions. Lesions >40 mm were excluded per protocol. The primary endpoint was the 3-year major adverse cardiac event (MACE) rate, defined as a composite of cardiac death, myocardial infarction (MI), and target vessel revascularization (TVR)., Results: The 3-year MACE rates in patients with short (<25 mm) vs. long (≥25-40 mm) lesions were 21.1% vs. 29.9% respectively (p = 0.055). The rate of cardiac death (6.5% vs. 7.8%, p = 0.592) and TVR (8.5% vs. 13.7%, p = 0.153) did not significantly differ. The rate of MI (CK-MB > 3× ULN) at 3 years was significantly higher in patients with long (≥25-40 mm) lesions (9.0% vs. 17.0%, p = 0.024), with the majority occurring in-hospital (7.0% vs. 13.6%, p = 0.037)., Conclusions: Patients with long (≥25-40 mm) calcified target lesions had similar outcomes in terms of MACE at 3 years despite higher rates of MI, which mostly occurred in-hospital. Using the more contemporary SCAI definition of MI, there was no significant difference in rates of MI between the short (<25 mm) and long (≥25-40 mm) groups. Further studies are warranted to determine how OA compares to focal force balloon angioplasty, rotational atherectomy and other novel treatment options for long severely calcified lesions., Summary for Annotated Table of Contents: Percutaneous coronary intervention of long calcified lesions is inherently more complex and higher risk and may require more intensive lesion preparation. This sub-analysis of ORBIT II revealed that orbital atherectomy treatment of longer (≥25-40 mm) lesions was associated with a higher rate of MACE at 30 days, but not at 3 years. This difference, however, was driven primarily by a higher in-hospital non-Q-wave MI rate; using the more contemporary SCAI definition of MI, there was no significant difference in rates of MI between the short (<25 mm) and long (≥25-40 mm) groups., Competing Interests: Declaration of competing interest Brad Martinsen and Ann Behrens are employed by and own stock in CSI. Jeffrey Chambers receives consulting fees from CSI. Gautam Kumar, Eric Youngyoon Shin, Rajesh Sachdeva, and Evan Shlofmitz have no relevant conflict of interest to disclose., (Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
17. Impact of age following treatment of severely calcified coronary lesions with the orbital atherectomy system: 3-year follow-up.
- Author
-
Lee MS, Shlofmitz RA, Martinsen BJ, Sethi S, and Chambers JW
- Subjects
- Age Factors, Aged, Aged, 80 and over, Coronary Angiography, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease mortality, Female, Humans, Male, Middle Aged, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention mortality, Postoperative Complications etiology, Prospective Studies, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, United States, Vascular Calcification diagnostic imaging, Vascular Calcification mortality, Atherectomy, Coronary adverse effects, Atherectomy, Coronary mortality, Coronary Artery Disease surgery, Vascular Calcification surgery
- Abstract
Objectives: We investigated the safety and efficacy of coronary orbital atherectomy to treat severely calcified lesions prior to stenting based upon age., Background: The ORBIT II study reported the safety and efficacy with orbital atherectomy in 443 patients with severely calcified lesions. Elderly patients undergoing percutaneous coronary intervention may be at increased risk for major adverse cardiac events (MACE) and death compared with younger patients., Methods: Patients were stratified according to age (≥75 year old [174/443, 39.3%] vs. <75 year old [269/443, 60.7%]). The MACE rate, defined as cardiac death, myocardial infarction (CK-MB > 3X ULN), and target vessel revascularization, was examined at 30-day and 3-year follow-up., Results: Elderly and non-elderly groups had similar rates of procedural (87.9% vs. 89.5%, p = 0.64) and angiographic success (91.4% vs. 91.4%, p = 1.00). Severe angiographic complications were also similar in both groups (6.9% vs. 7.4%, p = 1.00). There was no statistically significant difference in MACE rates in the elderly and younger groups at 30 days (10.9% vs. 10.1%; p = 0.76) and 3 years (27.8% vs. 20.7%, p = 0.13). The individual endpoints of cardiac death (9.1% vs. 5.1%, p = 0.14), myocardial infarction (13.4% vs. 9.7%, p = 0.27), and target vessel revascularization (10.6% vs. 10.0%, p = 0.91) were also similar in both groups at 3 years., Conclusions: The rates of adverse clinical events in elderly patients who underwent orbital atherectomy were low and similar to the non-elderly patients, suggesting that it could be a reasonable treatment strategy for elderly patients with severely calcified lesions., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
18. Orbital atherectomy for the treatment of small (2.5mm) severely calcified coronary lesions: ORBIT II sub-analysis.
- Author
-
Lee MS, Shlofmitz RA, Shlofmitz E, Srivastava PK, Kong J, Grines C, Revytak G, and Chambers JW
- Subjects
- Aged, Aged, 80 and over, Atherectomy, Coronary adverse effects, Atherectomy, Coronary mortality, Clinical Trials as Topic, Coronary Angiography, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease mortality, Coronary Vessels diagnostic imaging, Female, Humans, Male, Middle Aged, Multicenter Studies as Topic, Plaque, Atherosclerotic, Retrospective Studies, Risk Factors, Severity of Illness Index, Stents, Time Factors, Treatment Outcome, United States, Vascular Calcification diagnostic imaging, Vascular Calcification mortality, Atherectomy, Coronary methods, Coronary Artery Disease surgery, Coronary Vessels surgery, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention instrumentation, Percutaneous Coronary Intervention mortality, Vascular Calcification surgery
- Abstract
Objectives: We assessed the safety and efficacy of orbital atherectomy to modify severely calcified coronary plaque prior to stent implantation in patients with small vessel (2.5mm) disease., Background: Severe coronary artery calcification increases the risk of adverse clinical events during percutaneous coronary intervention (PCI). Patients who undergo PCI of small vessels have worse clinical outcomes including higher rates of perforation and dissection. The outcomes of orbital atherectomy of small diameter vessels (2.5mm) are unknown., Methods: ORBIT II was a single-arm, multicenter trial which prospectively enrolled patients with severely calcified coronary lesions treated with orbital atherectomy prior to stenting in 49U.S. sites. The primary endpoint was the 3year rate of major adverse cardiac events, which was the composite of cardiac death, myocardial infarction, and target vessel revascularization., Results: Of the 443 patients, 55 (12.4%) had reference vessel diameters (RVD) of 2.5mm and 388 (87.6%) had RVD >2.5. The rates of severe angiographic complications were similar in both groups. The primary endpoint was similar in both groups (30.6% vs. 22.5%, p=0.22), as were the rates of cardiac death (9.8% vs. 6.3%, p=0.33) and myocardial infarction (12.8% vs. 10.9%, p=0.67). Target vessel revascularization was numerically higher in the small vessel group (16.8% vs. 9.3%, p=0.13)., Conclusions: Patients with small coronary vessel disease had comparable clinical outcomes compared to the larger diameter group following orbital atherectomy. Subsequent studies are required to establish the optimal revascularization approach for such patients with small coronary vessel disease burdened by heavily calcified lesions., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
19. Orbital atherectomy for treating de novo, severely calcified coronary lesions: 3-year results of the pivotal ORBIT II trial.
- Author
-
Lee M, Généreux P, Shlofmitz R, Phillipson D, Anose BM, Martinsen BJ, Himmelstein SI, and Chambers JW
- Subjects
- Aged, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease mortality, Female, Humans, Male, Patient Selection, Prospective Studies, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, United States, Vascular Calcification diagnostic imaging, Vascular Calcification mortality, Atherectomy, Coronary adverse effects, Atherectomy, Coronary mortality, Coronary Artery Disease therapy, Percutaneous Coronary Intervention, Vascular Calcification therapy
- Abstract
Background/purpose: The presence of heavy coronary artery calcification increases the complexity of percutaneous coronary intervention (PCI) and increases the incidence of major adverse cardiac events (MACE): death, myocardial infarction (MI), target vessel revascularization (TVR), and stent thrombosis. The ORBIT II (Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions) trial reported low rates of procedural, 30-day, 1-year, and 2-year ischemic complications after treatment of de novo, severely calcified lesions with the Diamondback 360° Coronary Orbital Atherectomy System (OAS) (Cardiovascular Systems, Inc.)., Methods/materials: ORBIT II was a single-arm trial that enrolled 443 patients at 49U.S. sites; in this study, de novo, severely calcified coronary lesions were treated with OAS prior to stenting. The primary safety endpoint was 30-day MACE: the composite of cardiac death, MI, and TVR (inclusive of target lesion revascularization (TLR)). The primary efficacy endpoint was procedural success: stent delivery with a residual stenosis of <50% without the occurrence of in-hospital MACE.The present analysis reports the final, 3-year follow-up results from ORBIT II., Results: The majority of subjects (88.2%) underwent PCI with drug-eluting stents after orbital atherectomy. There were 360 (81.3%) subjects who completed the protocol-mandated 3-year visit.The overall cumulative rate of 3-year MACE was 23.5%, including cardiac death (6.7%), MI (11.2%), and TVR (10.2%). The 3-year target lesion revascularization rate was 7.8%., Conclusions: In the final 3-year analysis of the ORBIT II trial, orbital atherectomy of severely calcified coronary lesions followed by stenting resulted in a low rate of adverse ischemic events compared with historical controls.Orbital atherectomy represents a safe and effective revascularization strategy for patients with severely calcified coronary lesions., Summary: The ORBIT II trial enrolled 443 subjects to study orbital atherectomy followed by stenting for de novo severely calcified coronary lesions. The overall cumulative 3-year MACE rate was 23.5%, including cardiac death (6.7%), MI (11.2%), and TVR (10.2%); the 3-year target lesion revascularization rate was 7.8%. Orbital atherectomy of heavily calcified coronary lesions followed by stenting results in a low rate of adverse ischemic events compared with historical controls; it represents a reasonable revascularization strategy for patients with severely calcified coronary lesions., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
20. Atherectomy Devices for the Treatment of Calcified Coronary Lesions.
- Author
-
Chambers JW, Behrens AN, and Martinsen BJ
- Subjects
- Atherectomy instrumentation, Atherectomy, Coronary instrumentation, Coronary Angiography, Humans, Retrospective Studies, Severity of Illness Index, Stents, Treatment Outcome, United States, Atherectomy methods, Atherectomy, Coronary methods, Coronary Artery Disease surgery, Percutaneous Coronary Intervention, Vascular Calcification surgery
- Abstract
The presence of moderate and severe coronary artery calcification (CAC) is associated with higher rates of angiographic complications during percutaneous coronary intervention (PCI), as well as higher major adverse cardiac events compared with noncalcified lesions. Diabetes mellitus, a risk factor for CAC, is increasing in the United States. Vessel preparation before PCI with atherectomy can facilitate successful stent delivery and expansion that may otherwise not be possible. We review here CAC prevalence, risk factors, and impact on PCI, as well as the currently available coronary atherectomy devices including rotational atherectomy, orbital atherectomy, and laser atherectomy., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
21. Orbital atherectomy system in treating calcified coronary lesions: 3-Year follow-up in first human use study (ORBIT I trial).
- Author
-
Bhatt P, Parikh P, Patel A, Chag M, Chandarana A, Parikh R, and Parikh K
- Subjects
- Atherectomy, Coronary adverse effects, Atherectomy, Coronary mortality, Coronary Artery Disease diagnosis, Coronary Artery Disease mortality, Equipment Design, Feasibility Studies, Female, Humans, India, Male, Middle Aged, Myocardial Infarction etiology, Percutaneous Coronary Intervention instrumentation, Pilot Projects, Severity of Illness Index, Stents, Time Factors, Treatment Outcome, Vascular Calcification diagnosis, Vascular Calcification mortality, Atherectomy, Coronary instrumentation, Cardiac Catheters, Coronary Artery Disease therapy, Vascular Calcification therapy
- Abstract
Background/purpose: The ORBIT I trial evaluated the safety and performance of an orbital atherectomy system (OAS) in treating de novo calcified coronary lesions. Severely calcified coronary arteries pose ongoing treatment challenges. Stent placement in calcified lesions can result in stent under expansion, malapposition and procedural complications. OAS treatment may be recommended to facilitate coronary stent implantation in these difficult lesions., Materials/methods: Fifty patients with de novo calcified coronary lesions were enrolled in the ORBIT I trial. Patients were treated with the OAS followed by stent placement. Our institution treated 33/50 patients and continued follow-up for 3 years., Results: Average age was 54.4 years and 90.9% were males. Mean lesion length was 15.9mm. The average number of OAS devices used per patient was 1.3. Procedural success was achieved in 97% of patients. Angiographic complications were observed in five patients (two minor dissections, one major dissection and two perforations). The cumulative major adverse cardiac event (MACE) rate was 6.1% in-hospital, 9.1% at 30 days, 12.1% at 6 months, 15.2% at 2 years, and 18.2% at 3years. The MACE rate included two in-hospital non Q-wave myocardial infarctions (MI), one additional non Q-wave MI at 30 days leading to target lesion revascularization (TLR), and three cardiac deaths., Conclusions: The ORBIT I trial suggests that OAS treatment may offer an effective method to modify calcified coronary lesion compliance to facilitate optimal stent placement in these difficult-to-treat patients with acceptable levels of safety up to 3 years post-index procedure., (Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
22. High-speed rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: the randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) trial.
- Author
-
Abdel-Wahab M, Richardt G, Joachim Büttner H, Toelg R, Geist V, Meinertz T, Schofer J, King L, Neumann FJ, and Khattab AA
- Subjects
- Aged, Angioplasty, Balloon, Coronary adverse effects, Angioplasty, Balloon, Coronary mortality, Chi-Square Distribution, Coronary Angiography, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease mortality, Coronary Restenosis etiology, Coronary Thrombosis etiology, Disease-Free Survival, Female, Germany, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction etiology, Prospective Studies, Prosthesis Design, Time Factors, Treatment Outcome, Vascular Calcification diagnostic imaging, Vascular Calcification mortality, Angioplasty, Balloon, Coronary instrumentation, Atherectomy, Coronary adverse effects, Atherectomy, Coronary mortality, Cardiovascular Agents administration & dosage, Coronary Artery Disease therapy, Drug-Eluting Stents, Paclitaxel administration & dosage, Vascular Calcification therapy
- Abstract
Objectives: This study sought to determine the effect of rotational atherectomy (RA) on drug-eluting stent (DES) effectiveness., Background: DES are frequently used in complex lesions, including calcified stenoses, which may challenge DES delivery, expansion, and effectiveness. RA can adequately modify calcified plaques and facilitate stent delivery and expansion. Its impact on DES effectiveness is widely unknown., Methods: The ROTAXUS (Rotational Atherectomy Prior to TAXUS Stent Treatment for Complex Native Coronary Artery Disease) study randomly assigned 240 patients with complex calcified native coronary lesions to RA followed by stenting (n = 120) or stenting without RA (n = 120, standard therapy group). Stenting was performed using a polymer-based slow-release paclitaxel-eluting stent. The primary endpoint was in-stent late lumen loss at 9 months. Secondary endpoints included angiographic and strategy success, binary restenosis, definite stent thrombosis, and major adverse cardiac events at 9 months., Results: Despite similar baseline characteristics, significantly more patients in the standard therapy group were crossed over (12.5% vs. 4.2%, p = 0.02), resulting in higher strategy success in the rotablation group (92.5% vs. 83.3%, p = 0.03). At 9 months, in-stent late lumen loss was higher in the rotablation group (0.44 ± 0.58 vs. 0.31 ± 0.52, p = 0.04), despite an initially higher acute lumen gain (1.56 ± 0.43 vs. 1.44 ± 0.49 mm, p = 0.01). In-stent binary restenosis (11.4% vs. 10.6%, p = 0.71), target lesion revascularization (11.7% vs. 12.5%, p = 0.84), definite stent thrombosis (0.8% vs. 0%, p = 1.0), and major adverse cardiac events (24.2% vs. 28.3%, p = 0.46) were similar in both groups., Conclusions: Routine lesion preparation using RA did not reduce late lumen loss of DES at 9 months. Balloon dilation with only provisional rotablation remains the default strategy for complex calcified lesions before DES implantation., (Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
23. Comparison of drug-eluting versus bare-metal stents after rotational atherectomy for the treatment of calcified coronary lesions.
- Author
-
Mangiacapra F, Heyndrickx GR, Puymirat E, Peace AJ, Wijns W, De Bruyne B, and Barbato E
- Subjects
- Aged, Drug-Eluting Stents, Female, Humans, Male, Prospective Studies, Atherectomy, Coronary, Coronary Artery Disease surgery, Stents, Vascular Calcification therapy
- Published
- 2012
- Full Text
- View/download PDF
24. Prognostic value of number and site of calcified coronary lesions compared with the total score.
- Author
-
Williams M, Shaw LJ, Raggi P, Morris D, Vaccarino V, Liu ST, Weinstein SR, Mosler TP, Tseng PH, Flores FR, Nasir K, and Budoff M
- Subjects
- Adult, Aged, Calcinosis complications, Calcinosis diagnostic imaging, Calcinosis mortality, Cardiovascular Diseases metabolism, Cardiovascular Diseases mortality, Coronary Artery Disease complications, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease mortality, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Risk Assessment, Risk Factors, Severity of Illness Index, Survival Analysis, Time Factors, Tomography, X-Ray Computed, Calcinosis metabolism, Calcium analysis, Cardiovascular Diseases etiology, Coronary Artery Disease metabolism
- Abstract
Objectives: This study sought to evaluate the long-term prognostic value of the number and sites of calcified coronary lesions and to compare the accuracy of number of calcified lesions with the extent of total calcium score., Background: There is a strong relationship between mortality and total coronary artery calcium (CAC) score. It is not known whether the number of calcified lesions or their location influences outcome., Methods: A total of 14,759 asymptomatic patients were referred for evaluation of CAC scanning using electron beam tomography. Univariable and multivariable Cox proportional hazards models were developed to estimate time to all-cause mortality at, on average, 6.8 years (n = 281)., Results: Risk-adjusted annual mortality was 0.19% (95% confidence interval 0.18% to 0.21%) for patients without any calcified lesions. For patients with >20 lesions, annual risk-adjusted mortality exceeded 2% per year. Mortality rates were significantly higher for left main lesions as compared to other coronary arteries with annual mortality rates of 1.3%, 2.1%, 9.2%, and 13.6% for 1 to 2, 3 to 5, and > or =6 lesions, respectively (p < 0.0001). For left main CAC scores of 0 to 10, 11 to 100, 101 to 399, and 400 to 999, annual risk-adjusted mortality was 0.33%, 0.81%, 1.73%, and 7.71%, respectively (p < 0.0001). All 4 patients with a CAC score of > or =1,000 in the left main died during follow-up. However, patients with more frequent calcified lesions also had higher CAC scores. Specifically, > or =81% of patients with >10 calcified lesions also had a CAC score > or =100. With exception, for patients with CAC scores > or =1,000, annual mortality was dramatically higher at 3.0% to 4.5% for those with 1 to 5 calcified lesions as compared with 1.1% to 2.0% for those with 6 or more lesions (p < 0.0001)., Conclusions: We report that mortality rates increased proportionally with the number of calcified lesions. Although predictive information is contained in the number of calcified lesions, its added statistical value is minimal. With exception, patients with frequent lesions in the left main or those with a few large calcified lesions have a particularly high mortality risk.
- Published
- 2008
- Full Text
- View/download PDF
25. CD40-CD154 expression in calcified and non-calcified coronary lesions of patients with chronic renal failure.
- Author
-
Campean V, Neureiter D, Nonnast-Daniel B, Garlichs C, Gross ML, and Amann K
- Subjects
- Aged, Aged, 80 and over, B-Lymphocytes pathology, C-Reactive Protein metabolism, CD40 Antigens immunology, CD40 Ligand immunology, Calcinosis complications, Calcinosis pathology, Coronary Artery Disease complications, Coronary Artery Disease pathology, Endothelial Cells pathology, Female, Humans, Kidney Failure, Chronic complications, Kidney Failure, Chronic pathology, Macrophages pathology, Male, Middle Aged, Muscle, Smooth, Vascular pathology, Signal Transduction immunology, T-Lymphocytes pathology, Vasculitis complications, Vasculitis immunology, Vasculitis pathology, CD40 Antigens metabolism, CD40 Ligand metabolism, Calcinosis immunology, Coronary Artery Disease immunology, Kidney Failure, Chronic immunology
- Abstract
The high incidence of cardiovascular complications in patients with chronic renal failure (CRF) is partly explained by more aggressive atherosclerosis, i.e. increased incidence and severity of lesions with higher tendency to calcification. The pathogenesis of this accelerated atherosclerosis, however, is not completely understood. Among other risk factors, chronic micro-inflammation may be involved. Activation of cells and adhesion molecules in atherosclerosis is governed by CD40-CD154 (CD40 ligand) interaction. Therefore, we investigated the expression and distribution of CD40-CD154 in different coronary atherosclerotic lesions of CRF patients and non-renal control patients. Coronary plaques of 57 patients with and without CRF were categorized according to the Stary classification and analysed for in situ protein expression of CD40, CD154 and CRP using immunohistochemistry and a semiquantitative scoring system. The nature, number and distribution of infiltrating cells was analysed and correlated to the types of coronary lesions and in particular to the presence of calcification. CD40 was over expressed in media myocytes of coronary plaques of both uremic and control patients. Inside the plaques, CD40 was expressed on endothelial cells, T lymphocytes, macrophages, fibroblasts, and smooth muscle cells. CD154 expression was seen on T cells in areas densely infiltrated by CD40 positive macrophages. In uremic and control patients higher in situ expression of CD40, CD154 and CRP was seen in calcified compared to non-calcified lesions. Inside the plaques, there were significant differences in the expression pattern of CD40 and CD154 between uremic and control patients. In addition, in uremic patients coronary plaques showed higher CRP protein expression compared to control patients. The data indicate a higher inflammatory status of coronary lesions as well as involvement of the CD40-CD154 signaling cascade in CRF patients, especially in cases of calcified atherosclerotic lesions.
- Published
- 2007
- Full Text
- View/download PDF
26. Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Lesions: 1-Year Results From the Disrupt CAD III Study
- Author
-
Dean J. Kereiakes, MD, Jonathan M. Hill, MD, Richard A. Shlofmitz, MD, Andrew J. Klein, MD, Robert F. Riley, MD, Matthew J. Price, MD, Howard C. Herrmann, MD, William Bachinsky, MD, Ron Waksman, MD, and Gregg W. Stone, MD
- Subjects
Coronary artery disease ,Calcification ,Percutaneous coronary intervention ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background: Coronary calcification impairs stent delivery and optimal expansion, a significant predictor of subsequent stent thrombosis and restenosis. Current calcium ablative technologies may be limited by guidewire bias and periprocedural complications. Intravascular lithotripsy (IVL) delivers acoustic pressure waves to modify calcium, enhance vessel compliance, and optimize stent deployment. The Disrupt CAD III study demonstrated high (92.4%) procedural success and low (7.8%) 30-day major adverse cardiac event (MACE) rates following IVL, but longer term follow-up is required to determine the durability of clinical benefit and the late impact of optimized stent implantation associated with IVL. This analysis evaluates 1-year outcomes from the Disrupt CAD III study. Methods: Disrupt CAD III (NCT03595176) was a prospective, single-arm approval study designed to assess the safety and effectiveness of IVL as an adjunct to coronary stenting in de novo, severely calcified coronary lesions (n = 384). MACE was defined as the composite of cardiac death, myocardial infarction (MI), or ischemia-driven target vessel revascularization; target lesion failure was defined as cardiac death, MI, or ischemia-driven target lesion revascularization (ID-TLR). Results: At 1 year, MACE occurred in 13.8% of patients (cardiac death: 1.1%, MI: 10.5%, ischemia-driven target vessel revascularization: 6.0%) and target lesion failure occurred in 11.9% (ID-TLR: 4.3%), both driven by non-Q-wave MI (9.2%). Stent thrombosis (definite or probable) occurred in 1.1% of patients (including 1 event [0.3%] beyond 30 days). Conclusions: Disrupt CAD III represents the largest long-term (1-year) analysis of coronary IVL to date. IVL treatment prior to coronary stent implantation in severely calcified lesions was associated with low 1-year rates of MACE, ID-TLR, and stent thrombosis.
- Published
- 2022
- Full Text
- View/download PDF
27. Effectiveness and Safety of a Novel Intravascular Lithotripsy System for Severe Coronary Calcification: The CALCI-CRACK Trial.
- Author
-
Wang Q, Ma W, Zhang D, Zhang W, An J, Dou K, Li P, Jiang J, He Y, Tong Q, Zhang X, Pang W, Qiu C, Yang Q, Hu X, Zhong L, Cheng X, Peng X, Kan J, Zhang J, Zhang B, and Li Y
- Subjects
- Humans, Male, Female, Prospective Studies, Middle Aged, Aged, Treatment Outcome, Severity of Illness Index, China epidemiology, Follow-Up Studies, Coronary Vessels diagnostic imaging, Coronary Vessels pathology, Lithotripsy methods, Lithotripsy adverse effects, Vascular Calcification diagnosis, Vascular Calcification therapy, Coronary Angiography, Tomography, Optical Coherence methods, Coronary Artery Disease diagnosis, Coronary Artery Disease therapy
- Abstract
Background: Intravascular lithotripsy is effective and safe for managing coronary calcification; however, available devices are limited, and complex lesions have been excluded in previous studies. This study aimed to investigate the effectiveness and safety of a novel intravascular lithotripsy system for severe calcification in a population with complex lesions., Methods: CALCI-CRACK (treatment of severe calcified coronary lesions with a novel intracoronary shock wave lithotripsy system) (ChiCTR2100052058) was a prospective, single-arm, multicentre study. The primary end point was the procedural success rate. Major safety end points included major adverse cardiovascular events (MACE) and target lesion failure (TLF) at 30 days and 6 months, and severe angiographic complications. Calcification morphology was assessed in the optical coherence tomography (OCT) subgroup., Results: In total, 242 patients from 15 high-volume Chinese centres were enrolled, including 26.45% of patients with true bifurcation lesions, 3.31% with severely tortuous vessels, and 2.48% with chronic total occlusion, respectively. The procedural success rate was 95.04% (95% confidence interval 91.50%-97.41%), exceeding the prespecified performance goal of 83.4% (P < 0.001). The 30-day and 6-month MACE rates were 4.13% and 4.55%, respectively. TLF rates at those time points were 1.24% and 1.65%, respectively. Severe angiographic complications occurred in 0.42% of patients. In the OCT subgroup (n = 93), 93.55% of calcified lesions were fractured, and minimal lumen area increased from 1.55 ± 0.55 mm
2 to 4.91 ± 1.22 mm2 after stent implantation, with acute gain rate of 245 ± 102%., Conclusions: The novel intravascular lithotripsy system is effective and safe for managing severely calcified coronary lesions in a cohort that included true bifurcation lesions, severely tortuous vessels, and chronic total occlusion., Clinical Trial Registration: Chinese Clinical Trial Registry (ChiCTR), number ChiCTR2100052058., (Copyright © 2024 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
28. Long-term safety and performance of the orbital atherectomy system for treating calcified coronary artery lesions: 5-Year follow-up in the ORBIT I trial.
- Author
-
Bhatt P, Parikh P, Patel A, Chag M, Chandarana A, Parikh R, and Parikh K
- Subjects
- Adult, Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Percutaneous Coronary Intervention methods, Time Factors, Treatment Outcome, Atherectomy adverse effects, Atherectomy methods, Coronary Artery Disease therapy, Coronary Stenosis therapy, Coronary Vessels surgery, Myocardial Infarction therapy
- Abstract
Background/purpose: The ORBIT I trial, a first-in-man study, was conducted to evaluate the safety and performance of the orbital atherectomy system (OAS) in treating de novo calcified coronary lesions., Methods/materials: Fifty patients were enrolled between May and July 2008 based on several criteria, and were treated with the OAS followed by stent placement. The safety and performance of the OAS were evaluated by procedural success, device success, and overall major adverse cardiovascular event (MACE) rates, including cardiac death, myocardial infarction (MI) and need for target lesion revascularization (TLR). Our institution enrolled and treated 33 of the 50 patients and continued follow-up for 5 years., Results: Average age was 54 years and 91% were males. Mean lesion length was 15.9 mm. Device success was 100%, and average number of orbital atherectomy devices (OAD) used per patient was 1.3. Stents were placed directly after OAS in 31/32 patients (96.9%). All stents (average stent per lesion 1.1) were successfully deployed with 0.3% residual stenosis. The overall cumulative MACE rate was 6.1% in-hospital, 9.1% at 30 days, 12.1% at 6 months, 15.2% at 2 years, 18.2% at 3 years and 21.2% at 5 years (4 total cardiac deaths). None of the patients had Q-wave MIs. Angiographic complications were observed in 5 patients. No flow/slow flow due to distal embolization was observed., Conclusions: The ORBIT I trial suggests that OAS treatment continues to offer a safe and effective method to change compliance of calcified coronary lesions to facilitate optimal stent placement in these difficult-to-treat patients., (Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
29. Rational use of rotational atherectomy in calcified lesions in the drug-eluting stent era: Review of the evidence and current practice.
- Author
-
Tian W, Lhermusier T, Minha S, and Waksman R
- Subjects
- Angioplasty, Balloon, Coronary adverse effects, Atherectomy, Coronary adverse effects, Coronary Angiography methods, Coronary Artery Disease diagnostic imaging, Coronary Restenosis diagnostic imaging, Coronary Restenosis epidemiology, Coronary Restenosis therapy, Evidence-Based Medicine, Female, Follow-Up Studies, Humans, Male, Randomized Controlled Trials as Topic, Risk Assessment, Survival Rate, Time Factors, Treatment Outcome, Vascular Calcification diagnostic imaging, Vascular Calcification mortality, Angioplasty, Balloon, Coronary methods, Atherectomy, Coronary methods, Coronary Artery Disease therapy, Drug-Eluting Stents, Vascular Calcification therapy
- Abstract
Percutaneous coronary interventions of calcified coronary lesions are associated with worse clinical outcomes compared with noncalcified lesions and are still considered a technical challenge for interventional cardiologists. Rotational atherectomy (RA) can effectively optimize lesion preparation through plaque modification of heavily calcified coronary lesions. However, in conventional balloon angioplasty and bare metal stent eras, the use of RA was not associated with a significant improvement in restenosis and target lesion revascularization in patients with calcified lesions. Drug-eluting stents (DES) dramatically reduced the rates of restenosis and major adverse cardiac events. In the DES era, the need for RA is therefore questionable. Recently, some studies have reported clinical outcomes of patients with calcified lesions treated with DES and RA. In this article, we aim to critically review results from these randomized and observational clinical studies assessing the use of RA in the DES era., (Copyright © 2015. Published by Elsevier Inc.)
- Published
- 2015
- Full Text
- View/download PDF
30. A Prospective, Multicenter, Real-World Registry of Coronary Lithotripsy in Calcified Coronary Arteries: The REPLICA-EPIC18 Study.
- Author
-
Rodriguez-Leor O, Cid-Alvarez AB, Lopez-Benito M, Gonzalo N, Vilalta V, Diarte de Miguel JA, López LF, Jurado-Roman A, Diego A, Oteo JF, Cuellas C, Trillo R, Travieso A, Alfonso F, Carrillo X, Vegas-Valle JM, Cortes-Villar C, Pascual I, Muñoz Camacho JF, Flores X, Vera-Vera S, Moreu J, Barreira de Sousa G, Martí D, Jimenez-Mazuecos J, Fuertes M, Ocaranza R, de la Torre Hernandez JM, Lozano F, Solana Martinez SG, Gómez-Lara J, and Perez de Prado A
- Subjects
- Humans, Coronary Vessels, Prospective Studies, Treatment Outcome, Heart, Lithotripsy adverse effects, Acute Coronary Syndrome, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Vascular Calcification diagnostic imaging, Vascular Calcification therapy
- Abstract
Background: Intravascular lithotripsy (IVL) has demonstrated effectiveness in the treatment of calcified lesions in selected patients with stable coronary disease., Objectives: The authors sought to assess the performance of coronary IVL in calcified coronary lesions in a real-life, all comers, setting., Methods: The REPLICA-EPIC18 study prospectively enrolled consecutive patients treated with IVL in 26 centers in Spain. An independent core laboratory performed the angiographic analysis and event adjudication. The primary effectiveness endpoint assessed procedural success (successful IVL delivery, final diameter stenosis <20%, and absence of in-hospital major adverse cardiovascular events [MACE]). The primary safety endpoint measured freedom from MACE at 30 days. A predefined substudy compared outcomes between acute coronary syndrome (ACS) and chronic coronary syndrome (CCS) patients., Results: A total of 426 patients (456 lesions) were included, 63% of the patients presenting with ACS. IVL delivery was successful in 99% of cases. Before IVL, 49% of lesions were considered undilatable. The primary effectiveness endpoint was achieved in 66% of patients, with similar rates among CCS patients (68%) and ACS patients (65%). Likewise, there were no significant differences in angiographic success after IVL between CCS and ACS patients. The rate of MACE at 30 days (primary safety endpoint) was 3% (1% in CCS and 5% in ACS patients [P = 0.073])., Conclusions: Coronary IVL proved to be a feasible and safe procedure in a "real-life" setting, effectively facilitating stent implantation in severely calcified lesions. Patients with ACS on admission showed similar angiographic success rates but showed a trend toward higher 30-day MACE compared with patients with CCS. (REPLICA-EPIC18 study [Registry of Coronary Lithotripsy in Spain]; NCT04298307)., Competing Interests: Funding Support and Author Disclosures The study sponsor, Fundación EPIC, has received an institutional research grant from Shockwave Medical (Santa Clara, California, USA) to cover the design and maintenance costs of the electronic case report form. Shockwave Medical has had no influence on the study design or protocol in any respect. Shockwave Medical was not involved in the conduct of the study, including inclusion, follow-up, data collection, analysis, interpretation of results, drafting, and final approval of the protocol, nor in the genesis of this paper. Dr Rodriguez-Leor has received speaker honoraria and consulting fees from Medtronic and World Medica. Dr Pérez de Prado has received speaker honoraria and consulting fees from iVascular, Boston Scientific, Terumo, B. Braun, and Abbott Vascular. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
31. ShOckwave ballooN or Atherectomy with Rotablation in calcified coronary artery lesions: Design and rationale of the SONAR trial.
- Author
-
Bennett J, McCutcheon K, Ameloot K, Vanhaverbeke M, Lesizza P, Castaldi G, Adriaenssens T, Minten L, Palmers PJ, de Hemptinne Q, de Wilde W, Ungureanu C, Vandeloo B, Colletti G, Coussement P, Van Mieghem NM, and Dens J
- Subjects
- Humans, Prospective Studies, Coronary Vessels diagnostic imaging, Coronary Vessels surgery, Calcium, Coronary Angiography, Treatment Outcome, Atherectomy, Atherectomy, Coronary adverse effects, Drug-Eluting Stents, Vascular Calcification diagnostic imaging, Vascular Calcification therapy, Vascular Calcification etiology, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Coronary Artery Disease etiology, Myocardial Infarction etiology, Percutaneous Coronary Intervention adverse effects
- Abstract
Background: The percutaneous treatment of calcified coronary lesions remains challenging and is associated with worse clinical outcomes. In addition, coronary artery calcification is associated with more frequent peri-procedural myocardial infarction., Study Design and Objectives: The ShOckwave ballooN or Atherectomy with Rotablation in calcified coronary artery lesions (SONAR) study is an investigator-initiated, prospective, randomized, international, multicenter, open label trial (NCT05208749) comparing a lesion preparation strategy with either shockwave intravascular lithotripsy (IVL) or rotational atherectomy (RA) before drug-eluting stent implantation in 170 patients with moderate to severe calcified coronary lesions. The primary endpoint is difference in the rate of peri-procedural myocardial infarction. Key secondary endpoints include rate of peri-procedural microvascular dysfunction, peri-procedural myocardial injury, descriptive study of IMR measurements in calcified lesions, technical and procedural success, interaction between OCT calcium score and primary endpoint, 30-day and 1-year major adverse clinical events., Conclusions: The SONAR trial is the first randomized controlled trial comparing the incidence of peri-procedural myocardial infarction between 2 contemporary calcium modification strategies (Shockwave IVL and RA) in patients with calcified coronary artery lesions. Furthermore, for the first time, the incidence of peri-procedural microvascular dysfunction after Shockwave IVL and RA will be evaluated and compared., Competing Interests: Declaration of competing interest JB reports research grants and speaking fees from Abbott Vascular and Biotronik AG, and consulting fees from Biotronik AG, Boston Scientific and Elixir. NMVM reports research grant support from Abbott Vascular, Medtronic, Boston Scientific, Daiichi Sankyo, Astra Zeneca and advisory fees from Abbott Vascular, Medtronic, Boston Scientific, Daiichi Sankyo, Amgen, Anteris, JenaValve, Siemens, and Teleflex. JD reports consulting fees from Topmedical and Boston Scientific., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
32. EXpansion of stents after intravascular lithoTripsy versus conventional predilatation in CALCified coronary arteries.
- Author
-
Oomens T, Vos NS, van der Schaaf RJ, Amoroso G, Ewing MM, Patterson MS, Herrman JR, Slagboom T, and Vink MA
- Subjects
- Humans, Coronary Vessels diagnostic imaging, Coronary Vessels surgery, Coronary Vessels pathology, Prospective Studies, Treatment Outcome, Stents, Percutaneous Coronary Intervention adverse effects, Vascular Calcification diagnostic imaging, Vascular Calcification surgery, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease surgery, Lithotripsy adverse effects, Lithotripsy methods
- Abstract
Background: Coronary artery calcification is a strong predictor for procedural failure and is independently associated with adverse events after percutaneous coronary intervention (PCI). An important contributor to the impaired outcome is the inability to achieve optimal results due to stent underexpansion or stent deformation/fracture. Intravascular lithotripsy (IVL) has emerged as an alternative technique to change the integrity of calcified plaques., Aims: Our aim was to investigate if pre-treatment with IVL in severely calcified lesions increases stent expansion, assessed by optical coherence tomography (OCT), when compared to predilatation with conventional and/or specialty balloon strategy., Methods: EXIT-CALC was a prospective, single-centre, randomised controlled study. Patients with an indication for PCI and severe calcification of the target lesion were allocated to predilatation with conventional angioplasty balloons or pre-treatment with IVL, followed by drug-eluting stenting and mandatory postdilatation. Primary endpoint was stent expansion assessed by OCT. Secondary endpoints were the occurrence of peri-procedural events and major adverse cardiac events (MACE) in hospital and during follow-up., Results: A total of 40 patients were included. The minimal stent expansion in the IVL-group (n = 19) was 83.9 ± 10.3% and 82.2 ± 11.5% in the conventional group (n = 21) (p = 0.630). Minimal stent area was 6.6 ± 1.5 mm
2 and 6.2 ± 1.8 mm2 , respectively (p = 0.406). No peri-procedural, in-hospital and 30-day follow-up MACE were reported., Conclusions: In severely calcified coronary lesions we found no significant difference in stent expansion measured by OCT when comparing IVL, as plaque modification, with conventional and/or specialty angioplasty balloons., Competing Interests: Declaration of Competing Interest All authors declare that they have no conflicts of interest., (Copyright © 2023. Published by Elsevier B.V.)- Published
- 2023
- Full Text
- View/download PDF
33. Safety and Efficacy of OPN Balloon in Patients With Calcified Coronary Artery Disease.
- Author
-
Senguttuvan NB, Singh H, Kumar BV, Kongara RC, Abdulkader RS, Anandaram A, Krishnamurthy P, Balasubramaniyan JV, Sadhanandham S, Ramesh S, Manokar P, Muralidharan TR, Murthy JSN, and Thanikachalam S
- Subjects
- Humans, Prospective Studies, Coronary Angiography, Treatment Outcome, Stents, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Angioplasty, Balloon, Coronary, Atherectomy, Coronary methods, Vascular Calcification diagnostic imaging, Vascular Calcification therapy
- Abstract
Background: Patients with symptomatic calcified coronary lesions have poor outcomes. Such lesions require additional atherectomy devices for bed preparation., Aim: To assess the safety and efficacy of OPN balloon in patients with calcified coronary lesions., Methods: This is an investigator-initiated, prospective, observational study. The primary outcome of the study was a procedural success., Results: We studied 71 patients (133 lesions). Maximum lesions were located in LAD [46.6 %]. The OPN balloon was used for pre-dilatation alone in 28.6 % (Pre-stent OPN group), post-dilatation alone in 63.2 % of lesions (Post-stent OPN group), and in both situations in 8.3 % of lesions with procedural success in 98.5 % of patients. Further dilatation with different NC balloons was required in both groups (30 %). The median (IQR) OPN balloon diameter in the pre- and post-stent OPN group were 2.5 (2.5, 3.0) and 3.0 (3.0,3.0) mm (p = 0.001), respectively. The difference between the diameter of the stent and OPN balloon used in pre-stent OPN group was 0.5 (0.2, 0.5) mm while it was 0.0 (0.0,0.2) mm in the post-stent OPN group (p < 0.001). Eight complications and two deaths occured. Distal shaft rupture was also noticed., Conclusion: OPN balloon is safe, and effective in treating calcified coronary lesions. We propose to undersize the balloon by 0.5 mm for pre-dilatation followed by 0.25 mm larger NC balloon if needed. In the post-dilatation group, use a 1:1 size balloon in a non-tortuous straight segment. Use imaging especially when (1) the pressure taken more than the rated burst pressure, (2) an OPN balloon size is ≥3 mm (3) using 1:1 size OPN balloon in a tortuous segment., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
34. Intravascular Lithotripsy for the Treatment of Severely Calcified Coronary Artery Disease: A DISRUPT CAD III Intravascular Ultrasound Substudy.
- Author
-
Bhogal S, Garcia-Garcia HM, Klein A, Benzuly K, Mangalmurti S, Moses J, Alaswad K, Jaffer F, Yong C, Nanjundappa A, Ben-Dor I, Mintz GS, Hashim H, and Waksman R
- Subjects
- Humans, Constriction, Pathologic, Calcium, Treatment Outcome, Prospective Studies, Ultrasonography, Interventional, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Vascular Calcification diagnostic imaging, Vascular Calcification therapy, Lithotripsy adverse effects
- Abstract
Background: Coronary intravascular lithotripsy (IVL) has emerged as a novel technique for the treatment of severely calcified coronary lesions. We evaluated the mechanism and efficacy of IVL in facilitating optimal stent implantation in heavily calcified coronary lesions using intravascular ultrasound (IVUS)., Methods: Forty-six patients were initially enrolled as a part of the Disrupt CAD III study. Of these, 33 had pre-IVL, 24 had post-IVL, and 44 had post-stent IVUS evaluation. The final analysis was performed on 18 patients who had IVUS images interpretable at all three intervals. The primary endpoint was increase in minimum lumen area (MLA) from pre-IVL to post-IVL treatment to post-stenting., Results: Pre-IVL, MLA was 2.75 ± 0.84 mm
2 , percent area stenosis was 67.22 % ± 20.95 % with maximum calcium angle of 266.90° ± 78.30°, confirming severely calcified lesions. After IVL, MLA increased to 4.06 ± 1.41 mm2 (p = 0.0003), percent area stenosis decreased to 54.80 % ± 25.71 % (p = 0.0009), and maximum calcium angle decreased to 239.40° ± 76.73° (p = 0.003). There was a further increase in MLA to 6.84 ± 2.18 mm2 (p < 0.0001) and decrease in percent area stenosis to 30.33 % ± 35.08 % (p < 0.0001) post-stenting with minimum stent area of 6.99 ± 2.14 mm2 . The success rate of stent delivery, implantation, and post-stent dilation was 100 % post-IVL., Conclusion: In this first study evaluating the mechanism of IVL using IVUS, the primary endpoint of increase in MLA from pre-IVL to post-IVL treatment to post-stenting was successfully achieved. Our study showed that the use of IVL-assisted percutaneous coronary intervention is associated with improved vessel compliance, facilitating optimal stent implantation in de novo severely calcified lesions., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: All others have no conflicts of interest to declare., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
35. Percutaneous Coronary Intervention of Complex Calcific Coronary Lesions Utilizing Orbital Atherectomy Prior to Transcatheter Aortic Valve Replacement.
- Author
-
Beohar N, Mohammed N, Kherada N, Igyarto Z, and Martinsen BJ
- Subjects
- Aged, 80 and over, Atherectomy, Humans, Male, Retrospective Studies, Risk Factors, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Aortic Valve Stenosis complications, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis surgery, Atherectomy, Coronary adverse effects, Coronary Artery Disease complications, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Myocardial Infarction etiology, Percutaneous Coronary Intervention adverse effects, Transcatheter Aortic Valve Replacement adverse effects
- Abstract
Background: Coronary artery disease (CAD), often with severe calcification, is present in up to 75% of patients with severe aortic stenosis (AS) referred for transcatheter aortic valve replacement (TAVR). Management of CAD in such patients is challenging. Orbital atherectomy (OA) is an effective treatment of severely calcified coronary lesions prior to stent implantation. However, there is limited data on the use of OA for percutaneous coronary intervention (PCI) to treat calcific CAD patients prior to TAVR (OA PCI + TAVR)., Methods: Retrospective analysis of patients with moderate/severe calcific CAD and moderate/severe AS who underwent staged OA PCI + TAVR at one high-volume institution. Data were analyzed to assess the 1-year major adverse cardiac events after index OA PCI [MACE: death, target lesion revascularization (TLR), and myocardial infarction (MI)]., Results: There were 18 patients (mean age of 82) treated with staged OA PCI + TAVR, and of those, 10 (56%) were male, 7 (39%) Caucasian, and 11 (61%) Hispanic/Latino. The average left ventricular ejection fraction was 49% and congestive heart failure was present in 12 patients (67%). There were no angiographic complications (0%), stent thrombosis (0%), or stroke events (0%). The 30-day and 1-year MACE rates were 5.6% (0% death, 0% TLR, 5.6% MI) and 17% (0% death, 11% TLR, and 17% MI [all non-Q-wave MI]), respectively., Conclusions: In this single-center observational cohort series, patients with heavily calcified coronary lesions treated with OA prior to TAVR had low rates of MACE at 30 days and 1 year. The results demonstrate the feasibility and safety of OA for the treatment of complex calcific coronary lesions prior to TAVR. An up-to-date literature review of atherectomy before, during, or after TAVR in patients with concomitant severe AS and calcific CAD is also provided., Table of Contents Summary: There is limited data on the use of orbital atherectomy (OA) for percutaneous coronary intervention (PCI) to treat calcific coronary artery disease (CAD) patients prior to transcatheter aortic valve replacement (TAVR). Our primary aim was to evaluate the feasibility, safety, and 1-year outcome of OA PCI pre-TAVR in patients with complex CAD and severe aortic stenosis (AS). We also aimed to provide a brief up-to-date literature review of atherectomy before, during, or after TAVR in patients with concomitant severe AS and calcific CAD. This retrospective cohort study found that OA is feasible and safe for the treatment of severely calcified coronary lesions before TAVR, resulting in acceptable 30-day and 1-year outcomes., Competing Interests: Declaration of competing interest N. Beohar, N. Mohammed, and N. Kherada have no conflict of interest to declare. B. Martinsen and Zs. Igyarto are employed by and own stock in Cardiovascular Systems, Inc., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
36. [Why and how do I use the orbitalatherectomy ?]
- Author
-
Acheampong A and Monsegu J
- Subjects
- Coronary Angiography, Humans, Prospective Studies, Risk Factors, Severity of Illness Index, Treatment Outcome, Atherectomy, Coronary, Coronary Artery Disease surgery, Percutaneous Coronary Intervention, Vascular Calcification surgery
- Abstract
Severe coronary artery calcification, too often underestimated, increases the complexity of percutaneous coronary interventions. Atherectomy is one of preferred approach for the preparation of calcified lesions before stent placement. Orbital atherectomy (OA) is a new method that has proven to be safe and effective in the preparation of calcium plaques (ORBIT I and ORBIT II studies). The OA is made up of a crown mounted with diamonds that abrades the endoluminal calcium plaque by centrifugal force and creates pulsatile forces on the wall that fractures the deep calcified plaques in the media. The OA Diamondback 360 ™ consists of a tableside electric powered motor handle connected to a drive shaft mounted with an eccentric crown. The OA specific 0.012" coronary guidewire made of Nitinol (ViperWire ™) has 3 qualities; the torquability, the ease of navigation and the support. Compared to rotational atherectomy, AO is associated with a lower rate of MACE at 1 year, with less revascularization of the target vessel and reduced fluoroscopy time but at the cost of an increased rate of coronary dissection and perforation. AO is a new, quite attractive, safe and effective tool to consider in the preparation of calcified coronary lesions., (Copyright © 2021 Elsevier Masson SAS. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
37. Safety and effectiveness of percutaneous coronary intervention using rotational atherectomy and new-generation drug-eluting stents for calcified coronary artery lesions in patients with chronic kidney disease.
- Author
-
Malik FT, Kalimuddin M, Ahmed N, Badiuzzaman M, Khan AK, Dutta A, Huq TS, Banik D, Ahmed MN, Rahman MH, and Iqbal MAT
- Subjects
- Coronary Angiography, Coronary Vessels, Humans, Retrospective Studies, Treatment Outcome, Vascular Calcification complications, Vascular Calcification diagnosis, Vascular Calcification epidemiology, Atherectomy, Coronary, Coronary Artery Disease complications, Coronary Artery Disease diagnosis, Coronary Artery Disease surgery, Drug-Eluting Stents, Percutaneous Coronary Intervention, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic epidemiology
- Abstract
Aim: Coronary artery calcification is an important factor influencing revascularisation outcomes in patients with chronic kidney disease (CKD). Lesion preparation using rotational atherectomy (RA) may help adequately modify calcified plaques and facilitate the achievement of optimal clinical outcomes in these patients. In this study, we assessed the safety and effectiveness of percutaneous coronary intervention (PCI) using RA followed by new-generation drug-eluting stent (DES) implantation in patients with CKD and calcified coronary artery disease (CAD)., Methods and Results: From November 2014 to October 2019, a total of 203 patients with calcified CAD who underwent RA followed by second- or third-generation DES implantation at our centre were included in the study. Mild, moderate, and severe CKD was present in 38%, 55.5%, and 6.5% of the patients, respectively. Diffused coronary calcifications were present in 85%. Procedural success was 97.5% with minimal periprocedural complications. In-stent restenosis occurred in one patient (0.5%); major adverse cardiovascular and cerebrovascular events were reported in 22 patients (10.8%); cardiac death occurred in eight patients during follow-up., Conclusion: Percutaneous coronary intervention using RA followed by second- or third-generation DES implantation is feasible and safe with high procedural success and low in-stent restenosis in CKD patients with calcified coronary lesions., Competing Interests: Declaration of competing interest The authors have no conflicts of interest to declaration., (Copyright © 2021 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
38. "Rota-Tripsy": A Successful Combined Approach for the Treatment of a Long and Heavily Calcified Coronary Lesion.
- Author
-
Ielasi A, Loffi M, De Blasio G, and Tespili M
- Subjects
- Angioplasty, Balloon, Coronary, Atherectomy, Coronary, Coronary Angiography, Coronary Stenosis, Humans, Treatment Outcome, Coronary Artery Disease, Vascular Calcification
- Abstract
Heavily calcified coronary lesions remain a technical challenge and an important cause of stent under-expansion and then failure. We hereby present a successful case of combined rotational atherectomy and intravascular lithotripsy for the treatment of an un-dilatable, heavily calcified coronary stenosis., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
39. [Interests and limitations of percutaneous coronary intervention strategy in nonagenarian patients: A single center experience].
- Author
-
Sanoussi H, Bitton N, Kourireche N, Bernasconi F, Tounsi A, Bellemain-Appaix A, and Jacq L
- Subjects
- Aged, 80 and over, Female, Humans, Male, Retrospective Studies, Time Factors, Treatment Outcome, Coronary Artery Disease surgery, Percutaneous Coronary Intervention methods
- Abstract
Aim: To expose our center results in the angioplasty in nonagenarians and to evaluate its effectiveness but also the MACEs and the mortality in the short and long term., Methods: A retrospective study of 98 patients admitted to the Antibes hospital center from November 2013 to September 2018., Results: The median age was 91.8 [90.8-93.4]. 52.6% was male. 9.7% of the patients had a polyvascular site. 50.6% of patients had moderate renal failure. The radial approach was used in 88.4% of cases. 21.6% of patients had tri-truncal lesions, while 46.4% were monotruncular, LAD artery was the culprit artery in 67% of cases. One stent per lesion was used in the majority of cases. Our successful rate was 90%. After angioplasty, 96% of the patients underwent double antiaggregation platelet therapy, 74.4% under clopidogrel. The presence of arrhythmias before angioplasty, the femoral approach, the coronary dissection and cardiogenic shock after angioplasty were predictors of short- and long-term mortality. Diabetes, history of myocardial infarction, impaired left ventricular ejection fraction, calcified coronary lesions, occurrence of arrhythmias or signs of heart failure on post-procedure were predictors of MACE occurrence., Conclusions: This study demonstrates that angioplasty in selected population of nonagenarians is perfectly feasible with a good risk/benefit ratio and specifies the different predictors of MACE, both short- and long-term mortality., (Copyright © 2020 Elsevier Masson SAS. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
40. Safety of Same-Day Discharge after Percutaneous Coronary Intervention with Orbital Atherectomy.
- Author
-
Shlofmitz E, Jeremias A, Goldberg A, Pappas T, Berke A, Petrossian G, Tsiamtsiouris T, Lituchy A, Lee M, and Shlofmitz R
- Subjects
- Aged, Aged, 80 and over, Coronary Artery Disease diagnostic imaging, Female, Humans, Male, Middle Aged, Patient Readmission, Patient Safety, Registries, Retrospective Studies, Risk Assessment, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, Vascular Calcification diagnostic imaging, Atherectomy, Coronary adverse effects, Coronary Artery Disease therapy, Length of Stay, Patient Discharge, Percutaneous Coronary Intervention adverse effects, Vascular Calcification therapy
- Abstract
Background: Severely calcified lesions present many challenges to percutaneous coronary intervention (PCI). Orbital atherectomy (OA) aids vessel preparation and treatment of severely calcified coronary lesions. Same-day discharge (SDD) after PCI has numerous advantages including cost savings and improved patient satisfaction. The aim of this study is to evaluate the safety of SDD among patients treated with OA in a real-world setting., Methods: This was a single-center retrospective analysis of patients undergoing OA. In-hospital and 30-day outcomes were assessed for major adverse cardiac events (MACE), device-related events and hospital readmissions., Results: There were 309 patients treated with OA of whom 94 had SDD (30.4%). Among SDD patients, there were no acute procedural complications and all patients were safely discharged on the day of the procedure. MACE at 30 days occurred in 1 patient (1.06%) due to major bleeding in the setting of a gastric arteriovenous malformation. There were 8 patients with unplanned 30-day readmissions (8.5%)., Conclusion: SDD after OA in patients with heavily calcified lesions appears to be safe, with low rates of adverse events and readmissions in select patients. In patients with SDD treated with OA, unplanned readmission occurred at a similar rate to the statewide average 30-day PCI readmission rate. Larger studies are needed to confirm the safety of this treatment paradigm and the potential cost savings., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
41. Direct Stenting in Patients Treated with Orbital Atherectomy: An ORBIT II Subanalysis.
- Author
-
Shlofmitz E, Martinsen BJ, Behrens AN, Ali ZA, Lee MS, Puma JA, Shlofmitz RA, and Chambers JW
- Subjects
- Aged, Aged, 80 and over, Angioplasty, Balloon, Coronary adverse effects, Angioplasty, Balloon, Coronary mortality, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease mortality, Feasibility Studies, Female, Humans, Male, Middle Aged, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, United States, Vascular Calcification diagnostic imaging, Vascular Calcification mortality, Angioplasty, Balloon, Coronary instrumentation, Atherectomy, Coronary adverse effects, Atherectomy, Coronary mortality, Coronary Artery Disease therapy, Stents, Vascular Calcification therapy
- Abstract
Background: Direct stenting offers many potential advantages in appropriately selected lesions. Coronary artery calcification increases the complexity and risk of adverse events associated with percutaneous coronary intervention. This study aimed to examine the feasibility of direct stenting after treatment with orbital atherectomy (OA)., Methods: ORBIT II was a single-arm trial enrolling 443 subjects with de novo severely calcified coronary lesions treated with OA; direct stenting was utilized in 59.0% of cases. Procedural outcomes and 3-year major adverse cardiac event (MACE) rates were compared in subjects treated with pre-stent balloon dilatation versus direct stenting after OA., Results: Procedural success (84.2% vs. 93.3%; p = 0.004) was significantly higher in the direct stenting cohort. 3-year MACE occurred less frequently in the direct stenting cohort (29.9% vs. 19.1%; p = 0.006), driven by lower rates of myocardial infarction and target lesion revascularization. In a propensity matched analysis, procedural success and 3-year MACE rates were similar in the pre-stent balloon dilatation and direct stenting groups (85.0% vs. 91.8%; p = 0.122 and 28.2% vs. 19.6%; p = 0.078, respectively)., Conclusions: Orbital atherectomy facilitates direct stenting and is associated with high procedural success and favorable 3-year outcomes in carefully selected patients. Randomized studies are needed to assess the optimal strategy after lesion preparation with OA., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
42. Safety and efficacy of radial versus femoral access for rotational Atherectomy: A systematic review and meta-analysis.
- Author
-
Khan AA, Panchal HB, Zaidi SIM, Papireddy MR, Mukherjee D, Cohen MG, Banerjee S, Rao SV, Pancholy S, and Paul TK
- Subjects
- Aged, Aged, 80 and over, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease mortality, Female, Humans, Male, Middle Aged, Observational Studies as Topic, Punctures, Risk Assessment, Risk Factors, Treatment Outcome, Vascular Calcification diagnostic imaging, Vascular Calcification mortality, Atherectomy, Coronary adverse effects, Atherectomy, Coronary mortality, Catheterization, Peripheral adverse effects, Catheterization, Peripheral mortality, Coronary Artery Disease therapy, Femoral Artery diagnostic imaging, Radial Artery diagnostic imaging, Vascular Calcification therapy
- Abstract
Introduction: Over the recent years, there has been increased interest in the use of transradial (TR) access for percutaneous coronary intervention (PCI), including rotational atherectomy (RA). However, a large proportion of operators seem to be reluctant to use TR access for complex PCI including rotational atherectomy for heavily calcified coronary lesions., Methods: We searched MEDLINE, ClinicalTrials.gov and the Cochrane Library for studies comparing radial versus femoral access in patients undergoing RA. Studies were included if they reported at least one of the following outcomes in each group separately: major adverse cardiac events (MACE), major bleeding, stent thrombosis, myocardial infarction (MI), hospital length of stay, radiation exposure, procedure time, procedure success and all-cause mortality. Odds ratio (OR) or mean difference (MD) with 95% confidence interval (CI) were calculated and a p-value of <0.05 was considered as a level of significance., Results: This meta-analysis included 5 retrospective studies with 3315 patients undergoing RA via radial access and 5838 patients via femoral access. Radial access was associated with lower major access site bleeding (OR: 0.45, 95% CI: 0.31-0.67, p < 0.001), and radiation exposure (MD: -16.1, 95%CI: -25.4--6.7 Gy cm
2 , p = 0.0007). There were no significant differences observed in all-cause in-hospital mortality (OR: 0.92, 95% CI: 0.69-1.23, p = 0.58); MACE (OR: 0.80, CI: 0.63, 1.02, p = 0.08), stent thrombosis (OR: 0.28, 95%CI: 0.06-1.33 p = 0.11); and MI (OR: 0.43, 95%CI: 0.15-1.24, p = 0.12). There were no significant differences in hospital stay, procedure time or procedure success between the two groups (p > 0.05)., Conclusion: This meta-analysis of 9153 patients from observational studies demonstrates similar all-cause mortality, MACE, procedural success and procedural time during RA performed using TR access and TF access. However, TR access was associated with decreased access site bleeding and radiation exposure. Given the observational nature of these findings, a randomized controlled trial is warranted for further evidence., (Copyright © 2018 Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
43. Optical Coherence Tomography Characterization of Coronary Lithoplasty for Treatment of Calcified Lesions: First Description.
- Author
-
Ali ZA, Brinton TJ, Hill JM, Maehara A, Matsumura M, Karimi Galougahi K, Illindala U, Götberg M, Whitbourn R, Van Mieghem N, Meredith IT, Di Mario C, and Fajadet J
- Subjects
- Aged, Aged, 80 and over, Angioplasty, Balloon, Coronary adverse effects, Angioplasty, Balloon, Coronary instrumentation, Coronary Angiography, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease physiopathology, Coronary Circulation, Coronary Stenosis diagnostic imaging, Coronary Stenosis physiopathology, Coronary Vessels physiopathology, Female, Humans, Lithotripsy adverse effects, Male, Middle Aged, Predictive Value of Tests, Severity of Illness Index, Stents, Treatment Outcome, Vascular Calcification diagnostic imaging, Vascular Calcification physiopathology, Angioplasty, Balloon, Coronary methods, Coronary Artery Disease therapy, Coronary Stenosis therapy, Coronary Vessels diagnostic imaging, Lithotripsy methods, Tomography, Optical Coherence, Vascular Calcification therapy
- Abstract
Objectives: This study sought to determine the mechanistic effects of a novel balloon-based lithoplasty system on heavily calcified coronary lesions and subsequent stent placement using optical coherence tomography (OCT)., Background: The Shockwave Coronary Rx Lithoplasty System (Shockwave Medical, Fremont, California) delivers localized, lithotripsy-enhanced disruption of calcium within the target lesion (i.e., lithoplasty) for vessel preparation before stent implantation., Methods: We analyzed OCT findings in 31 patients in whom lithoplasty was used to treat severely calcified stenotic coronary lesions., Results: After lithoplasty, intraplaque calcium fracture was identified in 43% of lesions, with circumferential multiple fractures noted in >25%. The frequency of calcium fractures per lesion increased in the most severely calcified plaques (highest tertile vs. lowest tertile; p = 0.009), with a trend toward greater incidence of calcium fracture (77.8% vs. 22.2%; p = 0.057). Post-lithoplasty, mean acute area gain was 2.1 mm
2 , which further increased with stent implantation, achieving a minimal stent area of 5.94 ± 1.98 mm2 and mean stent expansion of 112.0 ± 37.2%. Deep dissections, as part of the angioplasty effect, occurred in 13% of cases and were successfully treated with stent implantation without incidence of acute closure, slow flow/no reflow, or perforation., Conclusions: High-resolution imaging by OCT delineated calcium modification with fracture as a major mechanism of action of lithoplasty in vivo and demonstrated efficacy in the achievement of significant acute area gain and favorable stent expansion., (Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
44. Contemporary clinical outcomes of patients treated with or without rotational coronary atherectomy--an analysis of the UK central cardiac audit database.
- Author
-
Cockburn J, Hildick-Smith D, Cotton J, Doshi S, Hanratty C, Ludman P, Robinson D, Redwood S, de Belder M, and de Belder A
- Subjects
- Aged, Aged, 80 and over, Atherectomy, Coronary adverse effects, Databases, Factual, Female, Follow-Up Studies, Humans, Male, Medical Audit, Middle Aged, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention mortality, Prevalence, Risk Factors, Survival Analysis, Treatment Outcome, United Kingdom epidemiology, Atherectomy, Coronary mortality, Coronary Artery Disease mortality, Coronary Artery Disease therapy, Vascular Calcification mortality, Vascular Calcification therapy
- Abstract
Introduction: Rotational atherectomy (RA) is widely used for treating calcified coronary lesions. Clinical data however remain limited., Methods: We assessed outcome and survival among patients undergoing percutaneous coronary intervention (PCI) with or without RA in the UK between September 2007 and March 2011., Results: Data from 221,669 percutaneous coronary intervention (PCI) procedures were analysed; 2152 patients (0.97%) underwent RA (RA+); the remainder underwent conventional PCI (RA-). RA+ patients were older (71.7±9.6 vs. 64.1±12.8 year; p<0.001), and had a higher incidence of diabetes (26.4% vs. 18.0%; p<0.001), hypertension, (61.9% vs. 49.4%; p<0.001), peripheral vascular disease (9.9% vs. 4.2%, p<0.001), cerebrovascular disease (5.5% vs. 3.4%, p<0.001), renal impairment (3.4% vs. 1.5%, p<0.001) and poor left ventricular function (11.4% vs. 4.3%,p<0.001). Procedural success was lower among RA+ patients (90.3% vs 94.6%; p<0.001) and procedural complications were more frequent (9.7% vs 5.4%; p<0.001). After 2.4±1.2 years follow-up, unadjusted Cox proportional hazard modeling demonstrated poorer survival for RA+ patients (HR 2.21, 95%CI 1.97-2.49; p<0.0001). This disadvantage remained after adjustment for adverse variables (HR 1.26, 95%CI 1.11-1.44; p=0.0004) and following propensity analysis. There was evidence however of improved survival for RA+ patients with left main stem disease (HR 0.52, 95%CI 0.35-0.75, p<0.0001), and peripheral vascular disease (HR 0.65, 95%CI 0.43-0.98, p<0.0005)., Conclusions: Rotational atherectomy was undertaken in patients with higher pre-procedural risk. Medium term survival was worse among patients undergoing rotational atherectomy, and this survival disadvantage remained after correction for available adverse factors. Rotational atherectomy however remains clinically useful for patients with calcified coronary lesions., (Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
45. Downsizing from 6-French to 5-French guiding catheter after transradial coronary rotational atherectomy: a way to cross resistant calcified lesions.
- Author
-
Dahdouh Z, Roule V, and Grollier G
- Subjects
- Aged, Aged, 80 and over, Angioplasty, Balloon, Coronary instrumentation, Coronary Angiography, Coronary Artery Disease diagnostic imaging, Equipment Design, Female, Humans, Male, Radial Artery, Severity of Illness Index, Stents, Treatment Outcome, Vascular Calcification diagnostic imaging, Atherectomy, Coronary instrumentation, Catheters, Coronary Artery Disease therapy, Vascular Calcification therapy
- Abstract
Some severe calcified coronary lesions may resist the advancement of the stent despite rotational atherectomy and balloon predilation, when used via the transradial approach due to a lack of support of the guiding catheter and may require switching to the femoral approach. The latter is known to have better support but with the increased risk of vascular access site complications. Deep engagement of the guiding catheter with preferring 5-French to 6-French to avoid coronary dissection provides an active support and may be a solution in such situations. We report two cases of patients with calcified coronary lesions, where rotational atherectomy and balloon predilation were not sufficient for the stent to cross the lesion and switching to 5-French guiding catheter allowing a safe deep engagement which was the solution using the transradial access., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
46. Safety and effectiveness of percutaneous coronary intervention using rotational atherectomy and new-generation drug-eluting stents for calcified coronary artery lesions in patients with chronic kidney disease
- Author
-
Tawfiq Shahriar Huq, Dhiman Banik, Mir Nesaruddin Ahmed, Md. Habibur Rahman, Abdul Kayum Khan, Mohammad Badiuzzaman, Nazir Ahmed, Md. Abu Tareq Iqbal, Ashok Dutta, Md. Kalimuddin, and Fazila-Tun-Nesa Malik
- Subjects
Atherectomy, Coronary ,medicine.medical_specialty ,RD1-811 ,medicine.medical_treatment ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Coronary Angiography ,Percutaneous coronary intervention ,Coronary artery disease ,Lesion ,03 medical and health sciences ,0302 clinical medicine ,Restenosis ,Internal medicine ,Chronic kidney disease ,medicine ,Diseases of the circulatory (Cardiovascular) system ,Humans ,030212 general & internal medicine ,Renal Insufficiency, Chronic ,Vascular Calcification ,Retrospective Studies ,business.industry ,Stent ,Rotational atherectomy ,Drug-Eluting Stents ,medicine.disease ,Coronary Vessels ,medicine.anatomical_structure ,Treatment Outcome ,RC666-701 ,Conventional PCI ,Cardiology ,Surgery ,Original Article ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Kidney disease ,Artery - Abstract
Aim Coronary artery calcification is an important factor influencing revascularisation outcomes in patients with chronic kidney disease (CKD). Lesion preparation using rotational atherectomy (RA) may help adequately modify calcified plaques and facilitate the achievement of optimal clinical outcomes in these patients. In this study, we assessed the safety and effectiveness of percutaneous coronary intervention (PCI) using RA followed by new-generation drug-eluting stent (DES) implantation in patients with CKD and calcified coronary artery disease (CAD). Methods and results From November 2014 to October 2019, a total of 203 patients with calcified CAD who underwent RA followed by second- or third-generation DES implantation at our centre were included in the study. Mild, moderate, and severe CKD was present in 38%, 55.5%, and 6.5% of the patients, respectively. Diffused coronary calcifications were present in 85%. Procedural success was 97.5% with minimal periprocedural complications. In-stent restenosis occurred in one patient (0.5%); major adverse cardiovascular and cerebrovascular events were reported in 22 patients (10.8%); cardiac death occurred in eight patients during follow-up. Conclusion Percutaneous coronary intervention using RA followed by second- or third-generation DES implantation is feasible and safe with high procedural success and low in-stent restenosis in CKD patients with calcified coronary lesions.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.